Clinical trials
Juvenile Psoriatic Arthritis clinical trials
Below are recruiting juvenile psoriatic arthritis clinical trials, each written for real people, not researchers. We’re tracking 17 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06751238RecruitingPhase 1
Secukinumab for children with psoriatic arthritis
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
Loma Linda, CaliforniaAges 2–17 - NCT06663332RecruitingPhase 3
Long-term study of guselkumab in children who previously took it
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
Atlanta, GeorgiaAges 3 years+ - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17 - NCT04804553RecruitingPhase 3
Apremilast for children with active juvenile psoriatic arthritis
This Phase 3 trial tests apremilast to treat active juvenile psoriatic arthritis (joint inflammation) in children and teens. You may be able to join if your child’s condition is active despite prior treatments or if they couldn’t tolerate them.
BregenzAges 5–17 - NCT04806620Recruiting
Online app study for brain inflammation lifestyle data
This study uses a digital platform (app/website) to collect lifestyle and symptom information to better understand brain inflammation. You may qualify if you have certain conditions like Long COVID, migraines, autoimmune disease, inflammatory gut issues, mood disorders, or if you are a healthy comparison person.
Delafield, WisconsinAges 2 years+ - NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT05767047RecruitingPhase 3
Apremilast study for children with mouth ulcers from Behçet’s
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
ThessalonikiAges 5–18 - NCT06668181RecruitingPhase 3
Study of bimekizumab for kids with certain types of juvenile arthritis
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
CalgaryAges 2–18 - NCT06718569Recruiting
Pain in Inflammatory Joint Diseases
This study looks at pain in people with inflammatory joint diseases. It aims to understand how pain changes when you start or switch to a newer type of arthritis medication.
OsloAges 18 years+ - NCT06869551RecruitingPhase 3
Testing a New Drug for Juvenile Psoriatic Arthritis
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
Lancaster, CaliforniaAges 5–17 - NCT07000916Recruiting
Follow-up study for new arthritis in kids and young adults
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
BrusselsAges 2–50 - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07386587Enrolling by invitationPhase 3
Methotrexate plus etanercept for juvenile arthritis
This study compares methotrexate alone versus methotrexate combined with etanercept to see which works better for children with polyarticular juvenile idiopathic arthritis. The goal is to help children achieve low disease activity quickly.
Lahore, Punjab ProvinceAges 2–16 - NCT06763783Enrolling by invitationPhase 4
Shingles vaccine study for people with rheumatic diseases
This study offers the Shingrix shingles vaccine for free to adults with inflammatory rheumatic diseases. It compares how well the vaccine works in people taking immune-suppressing drugs versus those not taking them.
LundAges 18 years+ - NCT03728478RecruitingPhase 3
Step-up and step-down treatment for newly diagnosed arthritis
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
Genova, GEAges 2–17 - NCT01277419Recruiting
Study of new cases of several spine, joint, and eye diseases
This study enrolls people who have recently been diagnosed with certain inflammatory conditions affecting the spine, joints, or the eye. Researchers are looking to better understand how these illnesses start and how they may be linked, which could help guide future care.
BerlinAges Any age - NCT07243782Recruiting
Study of Cosentyx for skin and joint conditions in Korea
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Seoul, SeoulAges 6–100
Hear when a new Juvenile Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Juvenile Psoriatic Arthritis trials by city
Studies with a site in or near these metro areas.
Juvenile Psoriatic Arthritis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for juvenile psoriatic arthritis?
- Yes. Clin2 currently lists 17 recruiting juvenile psoriatic arthritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a juvenile psoriatic arthritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a juvenile psoriatic arthritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.